骨转移瘤患者^(89)SrCl_2治疗前后外周血CD4^+CD25^+调节性T细胞及Foxp3 mRNA的表达变化

Effects of ^(89)SrCl_2 Treatment on CD4^+CD25^+ Regulatory T Cells and Its Foxp3 mRNA Expression in Cancer Patients with Bone Metastases

目的探讨骨转移瘤患者89SrCl2治疗前后外周血中CD4+CD25+调节性T细胞及Foxp3 mRNA的表达变化。方法采用流式细胞术检测57例骨转移瘤患者89SrCl2治疗前后外周血CD4+CD25+调节性T细胞的水平,并与25例健康成人进行比较。同时采用RT-PCR方法检测患者89SrCl2治疗前后及对照组外周血CD4+CD25+调节性T细胞Foxp3 mRNA的表达情况。结果骨转移瘤患者89SrCl2治疗前外周血中CD4+CD25+调节性T细胞占CD4+T细胞总数的11.3%±5.5%,高于健康对照组(5.6%±1.5%,P<0.01);89SrCl2治疗后患者外周血中CD4+CD25+调节性T细胞所占比例为10.4%±5.2%,低于89SrCl2治疗前(P<0.05);89SrCl2治疗后患者CD4+CD25+调节性T细胞Foxp3 mRNA的相对表达量为0.296±0.029,低于89SrCl2治疗前0.348±0.028(P<0.05);治疗有效组CD4+CD25+调节性T细胞的数量为9.3%±4.2%,低于无效组(12.9%±5.3%,P<0.01);有效组Foxp3 mRNA的相对表达量为0.254±0.025,低于无效组(0.397±0.029,P<0.01)。结论 Foxp3基因对CD4+CD25+调节性T细胞有重要的调节功能,骨转移瘤患者接受89SrCl2治疗后抑制了外周血中Foxp3mRNA水平和减少了CD4+CD25+调节性T细胞的数量。

Objective To study the influence of 89SrCl2 on CD4＋CD25＋ regulatory T cells and its Foxp3 mRNA expression in cancer patients with bone metastases.Methods Peripheral blood samples were collected from 57 patients with bone metastases cancer and 25 healthy controls,the amount of CD4＋CD25＋ regulatory T cells in peripheral blood was determined by flow cytometry,the expression level of Foxp3 mRNA in these regulatory T cells was detected by RT-PCR.Results The percentage of CD4＋CD25＋ regulatory T cells in CD4＋ cells was（11.3±5.5）% in the patients with bone metastases,which was significantly more than that（5.6±1.5）% in healthy control（P0.01）.After the treatment of 89SrCl2,it was decreased to（10.4±5.2）%,and the decrease was statistically significant（P0.05）.The expression level of Foxp3 mRNA was decreased significantly from 0.348±0.028 to 0.296±0.029 by the treatment of 89SrCl2（P0.05）.In addition,the amount of CD4＋CD25＋T cells in the patients obtaining 89SrCl2 therapeutic effects was（9.3±4.2）%,which was lower than that in those patients without effects（12.9±5.3）%（P0.01）.The relative expression level of Foxp3 mRNA was 0.254±0.025 in the patients obtaining therapeutic effects,which was also significantly less than that（0.397±0.029） in those patients without any effects（P0.01）.Conclusion Foxp3 gene play a pivotal role in the regulation of CD4＋CD25＋T cells.The treatment of 89SrCl2 could decrease the amount of CD4＋CD25＋T cells and down-regulate Foxp3 mRNA expression of these cells in bone metastases cancer patients.